RecruitingNot ApplicableNCT07418450
Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?
Discrimination of N2a and N2b by EBUS-TBNA: is a Needle Change Necessary? - a Prospective Pilot Study
Sponsor
University of Vienna
Enrollment
30 participants
Start Date
Nov 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Pulmonary lesion suspicious for lung cancer or histologically confirmed lung cancer
- indication for mediastinal staging
Exclusion Criteria1
- \-
Interventions
DIAGNOSTIC_TESTEBUS-TBNA
During EBUS staging, the needle well be changed between all lymph node stations in a first round. The EBUS staging will be repeated without the change of the needle between the lymph node stations.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07418450
Related Trials
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NCT071689933 locations
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
NCT0746584812 locations
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
NCT074399911 location
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
NCT074106761 location
Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
NCT073992101 location